Alnylam Pharmaceuticals
ALNY
#531
Rank
$43.59 B
Marketcap
$328.73
Share price
-0.65%
Change (1 day)
28.53%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): $1.80

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is $1.80. In 2023 the company made an earnings per share (EPS) of -$3.53 an increase over its 2022 EPS that were of -$9.29.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)$1.80
2023-$3.53-62%
2022-$9.2929.03%
2021-$7.20-3.36%
2020-$7.45-8.48%
2019-$8.147.67%
2018-$7.5639.74%
2017-$5.4112.94%
2016-$4.7938.84%
2015-$3.45-32.88%
2014-$5.14259.44%
2013-$1.43-31.25%
2012-$2.08

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
$7.20 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$2.07 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
$43.12 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-$2.74-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-$0.73-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-$0.24-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
$1.24-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
$0.35-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA